Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

should be classified as a reduction of equity and, accordingly, did not record any reserve charges during the first quarter of 2009. These decreases were partially offset by a $0.1 million increase in professional fees associated with the preparation of the Company's SEC filings.

The Company recorded net interest and other expense of $1.2 million for the first quarter of 2009 compared to net interest and other income of $0.1 million for the first quarter of 2008. The decrease in net interest and other income resulted from an additional impairment in the amount of $0.9 million to the Company's auction rate securities due primarily to their continued illiquidity and a $0.4 million decrease in interest income, due to a decrease in cash and short-term investments during the quarter.

As a result, the Company's net loss for the quarter ended March 31, 2009 was $8.3 million compared to a net loss of $7.8 million for the quarter ended March 31, 2009. The loss for the quarter ended March 31, 2008 includes a loss from discontinued operations of $0.7 million.

As of March 31, 2009, the Company had $25.6 million in cash and investments (including auction rate securities recorded at their fair value) compared to $33.9 million as of December 31, 2008. The decrease of $8.3 million was due to cash spent during the first quarter of $7.4 million and an impairment to the auction rate securities of $0.9 million discussed above. Cash and short-term investments as of March 31, 2009 are net of $2.1 million in cumulative impairment charges recorded for the company's auction rate securities. Based on the amount of cash and short-term investments on hand, the $11.0 million received from the sale of common stock to Cadila on April 1, 2009, the approximately $7.5 million received from sales of common stock under the Wm Smith & Co. sales agreement through May 5, 2009, along with the Company's intention to pay 50% of the balance of its
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... “Our nation's healthcare system is broken, ... Furthermore, every governmental and professional entity that has ... of unorganized dysfunction shares in that enormous blame. ... as a device to use in an effort ... have accumulated through the years leading to the ...
(Date:8/21/2014)... A Finnish-Swedish research group at the Institute for ... Karolinska institutet, Stockholm, has developed a novel "man ... infection. This innovative diagnostic aid was described in ... August. The method is based on computer vision ... systems combined with visualization of only the diagnostically ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... Third Wave Technologies Inc. (Nasdaq: TWTI) today announced ... assays to RIKEN in Japan for use in various large ... Wave has been supplying its Invader SNP assays to Dr. ... Medicine at RIKEN, director of the Genome Center ...
... hit the road , ,MILWAUKEE - Ask any successful ... and you will get one answer: SALES. Despite this, sales ... in business school curricula today. What They Dont Teach You ... the Kellogg Alumni Club of Chicago titled Creating, Growing and ...
... between U.S. white collar workers and those in India is ... ,IT Manager ,U.S: $55,000 ,India: $8,500 , ,Accountant ,U.S.: $41,000 ... States were almost solely in the manufacturing sector, as more ... other Latin American countries to cut costs. Not to mention ...
Cached Biology Technology:Sales Strategies for the High-Tech Entrepreneur 2Sales Strategies for the High-Tech Entrepreneur 3Sales Strategies for the High-Tech Entrepreneur 4Sales Strategies for the High-Tech Entrepreneur 5Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 2Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 3
(Date:8/21/2014)... WHEN: , Saturday to Wednesday, Oct. 18-22, 2014 ... 111 W. Harbor Drive, San Diego, CA 92101 ... sessions and other presentations of the latest research ... Opening plenary session featuring high-scoring abstracts on rare ... of various cancers, and treatment for sun sensitivity ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
(Date:8/20/2014)... ITHACA, N.Y. In a study of 158 pregnant ... the craving and intentional consumption of ice, cornstarch, ... items, reports a new Cornell study. , Moreover, such ... teens who did not eat nonfood substances. , Pregnant ... low hemoglobin, which can lead to iron deficiency and ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Water and sunlight the formula for sustainable fuel 2Pica in pregnant teens linked to low iron 2
... tap the vast, unexplored reaches of the earth,s microbial ... DOE Joint Genome Institute (DOE JGI) has announced its ... undertake in the coming year. The 44 projects, culled ... Program (CSP), represent over 60 billion nucleotides of data ...
... in Spanish . Most of the functions ... proteins, which recognise their binding partner by affinity features localized ... however, the most complicated to study from the perspective of ... interaction is brief and occurs through a large section of ...
... trials to find a successful vaccine against footrot in ... funding of $663,000 from Australian Wool Innovation (AWI) ... at Monash University,s Australian Research Council Centre of Excellence ... of Sydney. Chief investigator Professor Julian Rood said ...
Cached Biology News:US Department of Energy Joint Genome Institute announces new genome sequencing projects 2US Department of Energy Joint Genome Institute announces new genome sequencing projects 3US Department of Energy Joint Genome Institute announces new genome sequencing projects 4US Department of Energy Joint Genome Institute announces new genome sequencing projects 5US Department of Energy Joint Genome Institute announces new genome sequencing projects 6US Department of Energy Joint Genome Institute announces new genome sequencing projects 7Scientists reveal the key mechanisms for affinity between transient binding proteins 2Footrot vaccine closer than ever 2
... • Small design specifically for western blots ... are specifically designed for staining western blots. ... 25 mm) of the disposable tray requires ... significant cost savings to the user. Pour ...
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
Biology Products: